Alterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment

Bun Hee Lee, Jin Pyo Hong, Jung A. Hwang, Byung-Joo Ham, Kyoung Sae Na, Won Joong Kim, Jose Trigo, Yong Ku Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF), a potent angiogenetic factor, is a known neurotrophic factor. In this study, we examined plasma levels of VEGF in 50 patients with schizophrenia (SPR) and 50 healthy control subjects. We also explored any changes in plasma VEGF levels after 6-week treatment with antipsychotic agents in patients with schizophrenia. All subjects with schizophrenia were either medication-naïve or medication-free for at least 4 weeks before assessment. Plasma VEGF levels in all subjects were significantly correlated with smoking duration, which was considered to be a significant covariate. Pre-treatment plasma VEGF levels in patients with schizophrenia were significantly lower than those in healthy controls. Post-treatment VEGF levels were significantly increased in patients with schizophrenia. Plasma VEGF levels in patients with schizophrenia did not exhibit significant correlation with the total or subscale scores of the Positive and Negative Syndrome Scale (PANSS) either at baseline or at the end of the 6-week treatment. In conclusion, our findings reveal that plasma VEGF levels before treatment were lower in patients with schizophrenia and that their VEGF levels increased after treatment. Thus, VEGF may have a neuroprotective role in the improvement of schizophrenia or in the treatment effects of antipsychotics.

Original languageEnglish
Pages (from-to)95-99
Number of pages5
JournalPsychiatry Research
Volume228
Issue number1
DOIs
Publication statusPublished - 2015 Jul 30

Fingerprint

Vascular Endothelial Growth Factor A
Schizophrenia
Therapeutics
Antipsychotic Agents
Nerve Growth Factors
Healthy Volunteers
Smoking

Keywords

  • Antipsychotic agent
  • Schizophrenia
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Alterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment. / Lee, Bun Hee; Hong, Jin Pyo; Hwang, Jung A.; Ham, Byung-Joo; Na, Kyoung Sae; Kim, Won Joong; Trigo, Jose; Kim, Yong Ku.

In: Psychiatry Research, Vol. 228, No. 1, 30.07.2015, p. 95-99.

Research output: Contribution to journalArticle

Lee, Bun Hee ; Hong, Jin Pyo ; Hwang, Jung A. ; Ham, Byung-Joo ; Na, Kyoung Sae ; Kim, Won Joong ; Trigo, Jose ; Kim, Yong Ku. / Alterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment. In: Psychiatry Research. 2015 ; Vol. 228, No. 1. pp. 95-99.
@article{c2d98c40f8c749e09a606b2733027978,
title = "Alterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment",
abstract = "Vascular endothelial growth factor (VEGF), a potent angiogenetic factor, is a known neurotrophic factor. In this study, we examined plasma levels of VEGF in 50 patients with schizophrenia (SPR) and 50 healthy control subjects. We also explored any changes in plasma VEGF levels after 6-week treatment with antipsychotic agents in patients with schizophrenia. All subjects with schizophrenia were either medication-na{\"i}ve or medication-free for at least 4 weeks before assessment. Plasma VEGF levels in all subjects were significantly correlated with smoking duration, which was considered to be a significant covariate. Pre-treatment plasma VEGF levels in patients with schizophrenia were significantly lower than those in healthy controls. Post-treatment VEGF levels were significantly increased in patients with schizophrenia. Plasma VEGF levels in patients with schizophrenia did not exhibit significant correlation with the total or subscale scores of the Positive and Negative Syndrome Scale (PANSS) either at baseline or at the end of the 6-week treatment. In conclusion, our findings reveal that plasma VEGF levels before treatment were lower in patients with schizophrenia and that their VEGF levels increased after treatment. Thus, VEGF may have a neuroprotective role in the improvement of schizophrenia or in the treatment effects of antipsychotics.",
keywords = "Antipsychotic agent, Schizophrenia, Vascular endothelial growth factor",
author = "Lee, {Bun Hee} and Hong, {Jin Pyo} and Hwang, {Jung A.} and Byung-Joo Ham and Na, {Kyoung Sae} and Kim, {Won Joong} and Jose Trigo and Kim, {Yong Ku}",
year = "2015",
month = "7",
day = "30",
doi = "10.1016/j.psychres.2015.04.020",
language = "English",
volume = "228",
pages = "95--99",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Alterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment

AU - Lee, Bun Hee

AU - Hong, Jin Pyo

AU - Hwang, Jung A.

AU - Ham, Byung-Joo

AU - Na, Kyoung Sae

AU - Kim, Won Joong

AU - Trigo, Jose

AU - Kim, Yong Ku

PY - 2015/7/30

Y1 - 2015/7/30

N2 - Vascular endothelial growth factor (VEGF), a potent angiogenetic factor, is a known neurotrophic factor. In this study, we examined plasma levels of VEGF in 50 patients with schizophrenia (SPR) and 50 healthy control subjects. We also explored any changes in plasma VEGF levels after 6-week treatment with antipsychotic agents in patients with schizophrenia. All subjects with schizophrenia were either medication-naïve or medication-free for at least 4 weeks before assessment. Plasma VEGF levels in all subjects were significantly correlated with smoking duration, which was considered to be a significant covariate. Pre-treatment plasma VEGF levels in patients with schizophrenia were significantly lower than those in healthy controls. Post-treatment VEGF levels were significantly increased in patients with schizophrenia. Plasma VEGF levels in patients with schizophrenia did not exhibit significant correlation with the total or subscale scores of the Positive and Negative Syndrome Scale (PANSS) either at baseline or at the end of the 6-week treatment. In conclusion, our findings reveal that plasma VEGF levels before treatment were lower in patients with schizophrenia and that their VEGF levels increased after treatment. Thus, VEGF may have a neuroprotective role in the improvement of schizophrenia or in the treatment effects of antipsychotics.

AB - Vascular endothelial growth factor (VEGF), a potent angiogenetic factor, is a known neurotrophic factor. In this study, we examined plasma levels of VEGF in 50 patients with schizophrenia (SPR) and 50 healthy control subjects. We also explored any changes in plasma VEGF levels after 6-week treatment with antipsychotic agents in patients with schizophrenia. All subjects with schizophrenia were either medication-naïve or medication-free for at least 4 weeks before assessment. Plasma VEGF levels in all subjects were significantly correlated with smoking duration, which was considered to be a significant covariate. Pre-treatment plasma VEGF levels in patients with schizophrenia were significantly lower than those in healthy controls. Post-treatment VEGF levels were significantly increased in patients with schizophrenia. Plasma VEGF levels in patients with schizophrenia did not exhibit significant correlation with the total or subscale scores of the Positive and Negative Syndrome Scale (PANSS) either at baseline or at the end of the 6-week treatment. In conclusion, our findings reveal that plasma VEGF levels before treatment were lower in patients with schizophrenia and that their VEGF levels increased after treatment. Thus, VEGF may have a neuroprotective role in the improvement of schizophrenia or in the treatment effects of antipsychotics.

KW - Antipsychotic agent

KW - Schizophrenia

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84930042171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930042171&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2015.04.020

DO - 10.1016/j.psychres.2015.04.020

M3 - Article

VL - 228

SP - 95

EP - 99

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1

ER -